🇺🇸 FDA
Patent

US 8598139

Lipid formulated dsRNA targeting the PCSK9 gene

granted A61KA61K31/713A61K38/1709

Quick answer

US patent 8598139 (Lipid formulated dsRNA targeting the PCSK9 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/713, A61K38/1709, A61K47/545, A61K47/55